ClearPoint Neuro, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ClearPoint Neuro, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.97M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $31.39M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.96M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $20.55M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.30M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $12.83M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $11.22M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $7.35M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $7.38M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.75M | Mar 21, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.97M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $31.39M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.96M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $20.55M | Mar 12, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.69M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $19.12M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $13.61M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $13.53M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $11.12M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $9.12M | Mar 9, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.54M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($18.91M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($22.09M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($16.44M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($14.41M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($6.78M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($5.54M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($6.16M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($7.17M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.07M) | Mar 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.16M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($19.73M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($22.45M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($16.33M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($13.37M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($6.22M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($4.59M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($5.25M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($6.34M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.49M) | Mar 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.90M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $12.39M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $11.71M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $10.89M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $9.28M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $4.69M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.81M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $2.31M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.81M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.63M | Mar 21, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.50M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $11.99M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $11.76M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $9.61M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $8.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $5.27M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $4.30M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $4.33M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.05M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.19M | Mar 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.93M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($8.95M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($13.72M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($16.17M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($12.70M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($7.81M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($2.85M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($4.63M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($5.99M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.82M) | Mar 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $522.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $275.0K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $717.0K | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $253.0K | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $168.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $41.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $10.0K | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $63.5K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $26.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $101.0K | Mar 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.75M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $39.19M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $42.66M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $55.49M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $65.58M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $29.52M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $11.93M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $7.86M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $13.90M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.40M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.73M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $13.80M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $21.49M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $18.60M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.79M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $27.14M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $7.34M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $6.35M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.07M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.16M | Mar 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.02M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $25.39M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $21.17M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $36.89M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $48.79M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.38M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $4.59M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $1.51M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $5.83M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | ($756.1K) | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.47M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 17, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($216.91M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($191.37M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($172.46M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($150.37M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($133.93M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($119.52M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($112.74M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($107.20M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($101.04M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($93.87M) | Mar 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.92M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $20.10M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.14M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $27.62M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $54.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $20.10M | Mar 9, 2022 |
| FY2021 | Dec 31, 2019 | $5.70M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $3.10M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $9.29M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $3.32M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.08M | Mar 17, 2026 |
| FY2023 | Dec 31, 2023 | $9.95M | Mar 12, 2024 |
| FY2022 | Dec 31, 2022 | $9.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $9.84M | Mar 9, 2022 |
| FY2020 | Dec 31, 2020 | $21.28M | Mar 22, 2021 |
| FY2019 | Dec 31, 2019 | $2.07M | Mar 27, 2020 |
| FY2018 | Dec 31, 2018 | $3.48M | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | $4.92M | Mar 21, 2018 |
| FY2016 | Dec 31, 2016 | $4.49M | Mar 9, 2017 |
| FY2015 | Dec 31, 2015 | $8.11M | Mar 25, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29.37M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 27.62M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 24.65M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 24.58M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 23.67M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 17.05M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 15.24M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | 11.02M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 10.69M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 3.62M | Mar 21, 2018 |